Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma
NCT03223103Phase 1Active, not recruiting
- Start
- Mar 2018
- Primary completion
- May 2029
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PGV-001 in glioblastoma (GBM). Primary endpoints: Dose-limiting toxicities up to 10 years and Feasibility of Personalized MTA vaccine administration up to 42 weeks. Started Mar 2018; status: active, not recruiting.
02
Drugs
PGV-001
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03223103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223103.